{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:38:11Z","timestamp":1789749491109,"version":"4.0.1"},"reference-count":7,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jdcr.2026.02.026","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:40:23Z","timestamp":1771375223000},"page":"210-212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Successful use of spesolimab in refractory pyoderma gangrenosum"],"prefix":"10.1016","volume":"70","author":[{"given":"Alexa","family":"Lum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suraj","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Aron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Kartono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jdcr.2026.02.026_bib1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.7861\/clinmedicine.19-3-224","article-title":"Pyoderma gangrenosum\u2013a guide to diagnosis and management","volume":"19","author":"George","year":"2019","journal-title":"Clin Med"},{"issue":"18","key":"10.1016\/j.jdcr.2026.02.026_bib2","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa013383","article-title":"Skin ulcers misdiagnosed as pyoderma gangrenosum","volume":"347","author":"Weenig","year":"2002","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jdcr.2026.02.026_bib3","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/bjd.16401","article-title":"The PARACELSUS score: a novel diagnostic tool for pyoderma gangrenosum","volume":"180","author":"Jockenh\u00f6fer","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jdcr.2026.02.026_bib4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jdcr.2023.01.022","article-title":"Spesolimab use in treatment of pyoderma gangrenosum","volume":"34","author":"Gu\u00e9nin","year":"2023","journal-title":"JAAD Case Rep"},{"issue":"3","key":"10.1016\/j.jdcr.2026.02.026_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2025.05.1113","article-title":"59674 randomized phase 3 trial of spesolimab in patients with ulcerative pyoderma gangrenosum: a study protocol","volume":"93","author":"Lebwohl","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jdcr.2026.02.026_bib6","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.celrep.2015.12.072","article-title":"Neutrophil-derived proteases escalate inflammation through activation of IL-36 family cytokines","volume":"14","author":"Henry","year":"2016","journal-title":"Cel Rep"},{"key":"10.1016\/j.jdcr.2026.02.026_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1581996","article-title":"Case report: spesolimab for pyoderma gangrenosum in an undifferentiated oligoarthritis patient receiving anti-IL-17 therapy","volume":"16","author":"Xin","year":"2025","journal-title":"Front Immunol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626001050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626001050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:26:42Z","timestamp":1785281202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512626001050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":7,"alternative-id":["S2352512626001050"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.02.026","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful use of spesolimab in refractory pyoderma gangrenosum","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.02.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}